BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

U.S. Group Asks FDA To Ban AstraZeneca Cancer Drug


10/19/2005 5:12:55 PM

A last-chance lung cancer drug that helped patients in preliminary trials didn't do well in a follow up, a failure that surprised manufacturer AstraZeneca. The company is trying to determine why things didn't go better. The drug, Iressa, was approved by the Food and Drug Administration (news - web sites) in 2003 for use in advanced lung cancer patients for whom standard therapy is no longer effective. Studies showed Iressa shrank tumors in some terminally ill patients. But approval, based on preliminary studies, came with a requirement that the drug be further tested. In a follow-up study it failed to produce an improvement that was statistically significant, prompting AstraZeneca to stop promoting it and to advise doctors that it had failed to live up to expectations. On Friday the consumer group Public Citzen petitioned the FDA (news - web sites) to remove Iressa from the market because of its poor performance. The group had argued against the drug's approval, questioning its effectiveness and safety. AstraZeneca told an FDA advisory committee, meeting this week to review several cancer drugs, that it is conducting a detailed analysis of the trial.

Read at Reuters
Read at AP

Reuters
AP
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES